Abstract: The present invention relates to a Solid-Contact Ion-Selective Electrode (SC-ISE) and a method of producing a SC-ISE. The SC-ISE of the invention comprises at least one transition metal in a mixed redox state and is suitable for long-term deployment having a long term stability and thus limited need for calibration.

Abstract: There is presented an electrochemical sensor (100) for sensing nitrous oxide (N2O) in an associated volume (106), the sensor comprising a primary chamber (110), a secondary chamber (120) being placed adjacent the primary chamber (110), the secondary chamber (120) comprising electrodes for performing electrochemical measurements and furthermore an electrolyte comprising an aprotic solvent. A first membrane (114) and a secondary membrane (124) are permeable to nitrous oxide and may be arranged so as to separate the associated volume (106) from a primary volume (116) within the primary chamber (110), and the primary volume (116) from a secondary volume (126) within the secondary chamber (120), where the primary chamber (110) comprises means for hindering oxygen in passing into the secondary volume (126), and wherein the working electrode (104) comprises indium (In).

Abstract: There is presented an electrochemical sensor (100) for sensing nitrous oxide (N2O) in an associated volume (106), the sensor comprising a primary chamber (110), a secondary chamber (120) being placed adjacent the primary chamber (110), the secondary chamber (120) comprising electrodes for performing electrochemical measurements and furthermore an electrolyte comprising an aprotic solvent. A first membrane (114) and a secondary membrane (124) are permeable to nitrous oxide and may be arranged so as to separate the associated volume (106) from a primary volume (116) within the primary chamber (110), and the primary volume (116) from a secondary volume (126) within the secondary chamber (120), where the primary chamber (110) comprises means for hindering oxygen in passing into the secondary volume (126), and wherein the working electrode (104) comprises indium (In).

Abstract: Fusion proteins having sequences that target specific moieties such as carbohydrates, lipids, and/or proteins that are associated with certain cell types and/or pathogens; and a sequence that induces effector function are provided. The disclosure also provides nucleic acids encoding the fusion proteins, as well as pharmaceutical compositions, methods of use, and methods of treating conditions or diseases such as infectious diseases, cancers, immune related disorders and other ailments, that include the fusions proteins described herein.

Abstract: TNF binding polypeptides based on human tetranectin C-type lectin like domains (CTLD) with improved binding characteristics and improved efficacy. The polypeptides comprise a TNF binding domain having the amino acid sequence KRWS-RYF (SEQ ID NO:1). Also provided are methods of preparing the polypeptides of the invention. The polypeptides may be used for the preparation of pharmaceutical compositions, and for treatment of a subject having a pathology mediated by TNF, such as treatment of rheumatoid arthritis.

Abstract: Tetranectin trimerizing polypeptides and fusion proteins including the polypeptides and therapeutic polypeptides and proteins. Trimeric complexes of the polypeptides and fusion proteins. Pharmaceutical compositions of the polypeptides, fusion proteins and the trimeric complexes.

Abstract: TNF binding polypeptides based on human tetranectin C-type lectin like domains (CTLD) with improved binding characteristics and improved efficacy. The polypeptides comprise a TNF binding domain having the amino acid sequence KRWS-RYF (SEQ ID NO:1). Also provided are methods of preparing the polypeptides of the invention. The polypeptides may be used for the preparation of pharmaceutical compositions, and for treatment of a subject having a pathology mediated by TNF, such as treatment of rheumatoid arthritis.

Abstract: Interleuekin-1 receptor antagonists (IL-1Ra) including fusion proteins having a trimerizing domain and an IL-1Ra polypeptide sequence. The fusion proteins are part of trimeric complexes that are used in pharmaceutical compositions for treating diseases mediated by IL-1. Effective treatment of inflammatory diseases, such as rheumatoid arthritis and diabetes, are described.